CDCA7

Across TCGA pan-cancer cohorts, CDCA7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDCA7 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CDCA7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDCA7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUSC, LUAD, and UCEC are the cancer types where CDCA7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.126	0.664	.008	20	view →
LUAD	OS	Median	II,III,IV	0.173	0.750	.005	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.438	.016	10	view →
SKCM	DFS	Median	II,III,IV	0.864	0.559	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDCA7–LUSC (OS)

Open the LUSC breakdown →